NewAmsterdam Pharma NAMS Income Statement (2021-2026)

NASDAQ NAMS
$25.39 -0.46 (-1.78%)
As of: Sep 4, 2026 · 2:25 PM EDT
Reported Financials

NewAmsterdam Pharma Quarterly Income Statement

Periods 16 quarters
Latest Jun 2026

NewAmsterdam Pharma reported revenue of $3.70M and net income of -$64.50M for the quarter ended Jun 2026, down 80.7% year over year. This income statement covers 16 quarters of results from Dec 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Dec2021 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.) 24.13M81.56M81.77M82.32M82.47M82.47M89.72M90.02M92.17M108.06M112.17M112.51M113.17M114.40M116.64M117.65M
Revenue & cost
Revenue 8.63M1.72M2.94M0.80M1.40M2.28M29.11M12.77M2.98M19.14M0.35M0.03M3.04M3.70M
Operating items
Research & DevelopmentR&D 40.42M34.34M43.37M41.29M42.43M38.38M35.70M34.90M44.75M27.52M30.97M38.59M38.01M41.67M
Selling, General & AdministrativeSG&A 8.06M9.86M9.13M10.59M14.45M16.48M18.41M21.11M27.15M27.26M24.52M27.42M23.45M26.89M
Other Operating ExpensesOther Opex -0.00M
Operating ExpensesOpex 48.48M44.20M52.50M51.88M56.88M54.85M54.11M56.00M71.90M54.78M55.49M66.01M61.46M68.56M
Operating IncomeOp. Inc -39.85M-42.48M-49.56M-51.07M-55.48M-52.58M-25.00M-43.23M-68.92M-35.63M-55.14M-65.98M-58.42M-64.86M
EBIT -39.85M-42.48M-49.56M-51.07M-55.48M-52.58M-25.00M-43.23M-68.92M-35.63M-55.14M-65.98M-58.42M-64.86M
Non-operating items
Interest & Investment IncomeInt & Inv Inc 0.94M4.61M3.06M2.67M3.08M4.87M4.44M4.49M7.35M7.05M6.71M6.47M5.65M5.81M
Other Non Operating IncomeOther Non Op Inc. 3.07M-0.07M-3.15M5.22M-2.42M-0.99M4.68M-7.87M4.29M8.63M0.22M-0.08M-1.61M-0.53M
Net income details
EBT -42.02M-38.29M-47.13M-49.47M-93.77M-39.01M-16.65M-92.18M-39.53M-17.36M-72.00M-74.92M-48.44M-64.14M
Tax ProvisionsTaxes -0.00M
Profit After TaxPAT -42.02M-38.29M-47.13M-49.49M-93.77M-39.01M-16.65M-92.18M-39.56M-17.47M-72.00M-74.92M-49.01M-64.50M
Income from Continuing OperationsIncome (Continuing) -42.02M-38.29M-47.13M-49.47M-93.77M-39.01M-16.65M-92.18M-39.53M-17.36M-72.00M-74.92M-48.44M-64.14M
Consolidated Net IncomeConsol Net Inc. -42.02M-38.29M-47.13M-49.47M-93.77M-39.01M-16.65M-92.18M-39.53M-17.36M-72.00M-74.92M-48.44M-64.14M
Income towards Parent CompanyParent Net Inc -42.02M-38.29M-47.13M-49.47M-93.77M-39.01M-16.65M-92.18M-39.53M-17.36M-72.00M-74.92M-48.44M-64.14M
Net Income towards Common StockholdersNet Income -42.02M-38.29M-47.13M-49.47M-93.77M-39.01M-16.65M-92.18M-39.53M-17.36M-72.00M-74.92M-48.44M-64.14M
Additional items
EPS (Basic) -0.51-0.47-0.57-0.60-1.06-0.41-0.18-0.98-0.34-0.15-0.61-0.63-0.40-0.52
EPS (Diluted) -0.51-0.47-0.57-0.60-1.06-0.41-0.18-0.98-0.34-0.15-0.61-0.63-0.40-0.52
Shares Outstanding 24.13M81.56M81.63M82.06M82.47M82.16M88.38M94.71M94.75M94.36M116.12M118.56M119.00M118.42M121.72M123.37M
Shares Outstanding (Diluted)Shares Outstanding (Dil.) 11.33M18.97M81.63M82.06M82.47M82.16M88.38M94.71M94.75M94.36M116.12M118.56M119.00M118.42M121.72M123.37M
EBITDA -39.85M-42.48M-49.56M-51.07M-55.48M-52.58M-25.00M-43.23M-68.92M-35.63M-55.14M-65.98M-58.42M-64.86M
Tax Rate 0.01